All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 metastasis (bone) metastasis (brain) NO metastasis (brain) YES metastasis (liver ) metastasis (lung) metastasis (lymph node ) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mBC - TNBC - L1 - PDL1 positive, anti-PD-(L)1 vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpassion-130 (PDL1>1%), 2018 0.71 [0.54; 0.94]
KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03]
KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96]
0.79 [0.69 ; 0.90 ] IMpassion-130 (PDL1>1%), 2018, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 3 0% 1,328 low not evaluable PFS (extension)detailed results IMpassion-130 (PDL1>1%), 2018 0.63 [0.50; 0.80]
0.63 [0.50 ; 0.80 ] IMpassion-130 (PDL1>1%), 2018 1 0% 369 NA not evaluable progression or deaths (PFS)detailed results IMpassion-130 (PDL1>1%), 2018 0.62 [0.49; 0.78]
KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91]
KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88]
0.69 [0.60 ; 0.78 ] IMpassion-130 (PDL1>1%), 2018, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 3 0% 1,328 low not evaluable DORdetailed results IMpassion-130 (PDL1>1%), 2018 0.60 [0.42; 0.85]
0.60 [0.42 ; 0.85 ] IMpassion-130 (PDL1>1%), 2018 1 0% 369 NA not evaluable objective responses (ORR)detailed results IMpassion-130 (PDL1>1%), 2018 1.96 [1.29; 2.98]
KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80]
KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60]
1.55 [1.20 ; 2.00 ] IMpassion-130 (PDL1>1%), 2018, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020 3 18% 1,328 low not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 19:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 143
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563